N1-(2'-anilino-4,4'-bipyridin-2-yl)cyclopropane-1,1-dicarboxamide | 712270-08-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N1-(2'-anilino-4,4'-bipyridin-2-yl)cyclopropane-1,1-dicarboxamide
• 英文别名: 1-N'-[4-(2-anilinopyridin-4-yl)pyridin-2-yl]cyclopropane-1,1-dicarboxamide
• CAS: 712270-08-1
• 化学式: C₂₁H₁₉N₅O₂
• 分子量: 373.414
• InChiKey: MCDUGYZETPDVRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-phenyl-4,4'-bipyridine-2,2'-diamine 、 1-氨基甲酰-1-环丙烷羧酸 在 N-[(dimethylamino)(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methylmethanaminium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 16.0h， 以48%的产率得到N1-(2'-anilino-4,4'-bipyridin-2-yl)cyclopropane-1,1-dicarboxamide
  参考文献：
  名称：

  [EN] PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE
  [FR] DERIVES PYRIDINE SERVANT D'INHIBITEURS DE JNK ET UTILISATION

  摘要：

  本发明涉及公式（I）的新化合物，其中：R1是芳基或杂环芳基，每个都可以选择地用一个或多个R3，OR3，OCOR3，COOR3，COR3，CONR3R4，NHCOR3，NR3R4，NHSO2R3，SO2R3，SO2NR3R4，SR3，CN，卤素或NO2取代；R2是R5，R6，COR5，COR6，CONHR5，CONHR6，CON（R6）2，COOR5，COOR6，SO2R5或SO2R6；一种用于它们的制备的方法和在其中使用的新中间体，含有所述治疗活性化合物的药物配方以及所述活性化合合物在治疗中的使用。

  公开号：

  WO2004052880A1

文献信息

• Therapeutic methods for type I diabetes
  申请人：Davis J. Roger

  公开号：US20060223807A1

  公开（公告）日：2006-10-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.

  本发明涉及 I 型糖尿病的治疗和预防。更具体地说，本发明涉及通过抑制 JNK2、选择性抑制 JNK2 或抑制 MAPK9 基因或基因产物的表达来治疗或防止机体免疫系统破坏 β 细胞（即胰岛中的胰岛素分泌细胞）的化合物。在一个实施方案中，本发明考虑诊断、鉴定、生产和使用调节 MAPK9 基因表达或 MAPK9 基因产物活性的化合物，包括但不限于 JNK2、编码 MAPK9 的核酸及其同源物、类似物和缺失物，以及反义、核糖酶、三重螺旋、抗体和多肽分子以及无机小分子。本发明考虑了此类化合物的各种药物制剂和给药途径。
• Therapeutic Methods For Type I Diabetes
  申请人：Davis Roger J.

  公开号：US20120208846A1

  公开（公告）日：2012-08-16

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• Therapeutic Methods for Type I Diabetes
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20150313881A1

  公开（公告）日：2015-11-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
• US7897572B1
  申请人：——

  公开号：US7897572B1

  公开（公告）日：2011-03-01
• US8501812B2
  申请人：——

  公开号：US8501812B2

  公开（公告）日：2013-08-06